Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use)
Athena Philis-Tsimikas, Meryl Brod, Marcus Niemeyer, Ann Marie Ocampo Francisco, Jeffrey Rothman, Athena Philis-Tsimikas, Meryl Brod, Marcus Niemeyer, Ann Marie Ocampo Francisco, Jeffrey Rothman
Abstract
Introduction: Insulin degludec (IDeg) is a new basal insulin in development with a flat, ultra-long action profile that may permit dosing using a simplified titration algorithm with less frequent self-measured blood glucose (SMBG) measurements and more simplified titration steps than currently available basal insulins.
Methods: This 26-week, multi-center, open-label, randomized, treat-to-target study compared the efficacy and safety of IDeg administered once-daily in combination with metformin in insulin-naïve subjects with type 2 diabetes using two different patient-driven titration algorithms: a "Simple" algorithm, with dose adjustments based on one pre-breakfast SMBG measurement (n = 111) versus a "Step-wise" algorithm, with adjustments based on three consecutive pre-breakfast SMBG values (n = 111). IDeg was administered using the FlexTouch® insulin pen (Novo Nordisk A/S, Bagsværd, Denmark), with once-weekly dose titration in both groups.
Results: Glycosylated hemoglobin (HbA1c) decreased from baseline to week 26 in both groups (-1.09%, IDegSimple; -0.93%, IDegStep-wise). IDegSimple was non-inferior to IDegStep-wise in lowering HbA1c [estimated treatment difference (IDegSimple - IDegStep-wise): -0.16% points (-0.39; 0.07)95% CI]. Fasting plasma glucose was reduced (-3.27 mmol/L, IDegSimple; -2.68 mmol/L, IDegStep-wise) with no significant difference between groups. Rates of confirmed hypoglycemia [1.60, IDegSimple; 1.17, IDegStep-wise events/patient year of exposure (PYE)] and nocturnal confirmed hypoglycemia (0.21, IDegSimple; 0.10, IDegStep-wise events/PYE) were low, with no significant differences between groups. Daily insulin dose after 26 weeks was 0.61 U/kg (IDegSimple) and 0.50 U/kg (IDegStep-wise). No significant difference in weight change was seen between groups by week 26 (+1.6 kg, IDegSimple; +1.1 kg, IDegStep-wise), and there were no clinically relevant differences in adverse event profiles.
Conclusion: IDeg was effective and well tolerated using either the Simple or Step-wise titration algorithm. While selection of an algorithm must be based on individual patient characteristics and goals, the ability to attain good glycemic control using a simplified titration algorithm may enable patient empowerment through self-titration, improved convenience, and reduced costs.
Trial registration: ClinicalTrials.gov NCT01326026.
Figures
References
- American Diabetes Association Standards of Medical Care in Diabetes—2012. Diabetes Care. 2012;35:S11–S63. doi: 10.2337/dc12-s011.
- International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. 2005. (Accessed 19 Dec 2012).
- Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Canadian Diabetes Association. Can J Diabetes. 2008;32:S1–S201.
- Meneghini L, Koenen C, Wenig W, Selam J-L. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes–results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007;9:902–913. doi: 10.1111/j.1463-1326.2007.00804.x.
- Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes. Diabetes Care. 2005;28:1282–1288. doi: 10.2337/diacare.28.6.1282.
- LANTUS® [insulin glargine (rDNA origin) injection]. Sanofi-aventis U.S. LLC, Bridgewater, NJ, USA; 2007. Health Care Professional. Dosing & Titration. (Accessed 13 Nov 2012).
- Benjamin EM. Self-monitoring of blood glucose: the basics. Clin Diabetes. 2002;20:45–47. doi: 10.2337/diaclin.20.1.45.
- White RD. Patient empowerment and optimal glycemic control. Curr Med Res Opin. 2012;28:979–989. doi: 10.1185/03007995.2012.677417.
- American Diabetes Association Insulin administration. Diabetes Care. 2002;25:S112–S115. doi: 10.2337/diacare.25.4.742.
- Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy Study. Diabetes Obes Metab. 2012;14:1081–1087.
- Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in insulin therapy study. Diabet Med. 2012;29:682–690. doi: 10.1111/j.1464-5491.2012.03605.x.
- Norris SL, Lau J, Smith SJ, et al. Self-management education for adults with type 2 diabetes: a meta-analysis on the effect of glycemic control. Diabetes Care. 2002;25:1159–1171. doi: 10.2337/diacare.25.7.1159.
- Kulzer B, Hermanns N, Reinecker H, Haak T. Effects of self-management training in type 2 diabetes: a randomized, prospective trial. Diabet Med. 2007;24:415–423. doi: 10.1111/j.1464-5491.2007.02089.x.
- Anderson RM, Funnell MM, Butler PM, et al. Patient empowerment: results of a randomized controlled trial. Diabetes Care. 1995;18:943–949. doi: 10.2337/diacare.18.7.943.
- Liebl A, Breitscheidel L, Nicolay C, Happich M. Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study. Curr Med Res Opin. 2008;24:2349–2358. doi: 10.1185/03007990802292728.
- Yeaw J, Christensen TE, Groleau D, Wolden ML, Lee WC. Self-monitoring blood glucose test strip utilization in Canada. Diabetes. 2012;61(Suppl 1):A35.
- Yeaw J, Lee WC, Wolden ML, Christensen T, Groleau D. Cost of self-monitoring of blood glucose in Canada among patients on an insulin regimen for diabetes. Diabetes Ther. 2012;3:7. doi: 10.1007/s13300-012-0007-6.
- Yeaw J, Lee WC, Aagren M, Christensen TJ. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. J Manag Care Pharm. 2012;18:21–32.
- Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859–864. doi: 10.1111/j.1463-1326.2012.01627.x.
- Heise T, Nosek L, Hovelmann U, Bøttcher SG, Hastrup H, Haahr H. Insulin degludec 200 U/mL is ultra-long-acting and has a flat and stable glucose-lowering effect. Diabetes. 2012;61:A91.
- Korsatko S, Deller S, Zahiragic S, et al. Ultra-long-acting insulin degludec: bio-equivalence and similar pharmacodynamics shown for two different formulations (U100 and U200) Diabetologia. 2011;54:S427.
- World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects—last amended by the 59th WMA General Assembly, Seoul; 2008. (Accessed 4 Jan 2013).
- International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice. E6 (R1), Step 4. 10-6-1996. (Accessed 4 Jan 2013).
- Niskanen L, Jensen LE, Råstam J, Nygaard-Pedersen L, Erichsen K, Vora JP. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther. 2004;26:531–540. doi: 10.1016/S0149-2918(04)90055-0.
- Garg S, Bailey T, DeLuzio T, Pollum D. Preference for a new prefilled insulin pen compared with the original pen. Curr Med Res Opin. 2011;27:2323–2333. doi: 10.1185/03007995.2011.630721.
- Garber AJ, King AB, Del Prato S, on behalf of the NN1250-3582 BEGIN BB T2D trial investigators et al. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1498–1507. doi: 10.1016/S0140-6736(12)60205-0.
- Zinman B, Philis-Tsimikas A, Cariou B, on behalf of the NN1250-3579 BEGIN Once Long trial investigators et al. Insulin degludec versus insulin glargine in insulin-naïve patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long) Diabetes Care. 2012;35:2464–2471. doi: 10.2337/dc12-1205.
- Bergenstal R, Bhargava A, Jain RK, et al; on behalf of the NN1250-3672 BEGIN Low Volume trial investigators. 200 U/ml insulin degludec improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve people with type 2 diabetes. Abstract 207. (Accessed 19 Jan 2013).
- Onishi Y, Ono Y, Rabl R, Endahl L, Nakamura S. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled on oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab. 2013 (Epub ahead of print).
- Blonde L, Merilainen M, Karwe V, Raskin P, for the TITRATE Study Group Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE study. Diabetes Obes Metab. 2009;11:623–631. doi: 10.1111/j.1463-1326.2009.01060.x.
- Gerstein HC, Yale J-F, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study. Diabet Med. 2006;23:736–742. doi: 10.1111/j.1464-5491.2006.01881.x.
- Davies M, Lavalle-González F, Storms F, Gomis R, on behalf of the AT.LANTUS Study Group Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diab Obes Metab. 2008;10:387–399. doi: 10.1111/j.1463-1326.2008.00873.x.
- Yki-Järvinen H, Juurinen L, Alvarsson M, et al. Initiate insulin by aggressive titration and education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 2007;30:1364–1369. doi: 10.2337/dc06-1357.
- Rakel RE. Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy. Adv Ther. 2009;26:838–846. doi: 10.1007/s12325-009-0061-2.
- Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin. 2011;27:13–20. doi: 10.1185/03007995.2011.621416.
- Reimer T, Hohberg C, Pfützner AH, Jørgensen C, Jensen KH, Pfützner A. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. Clin Ther. 2008;30:2252–2262. doi: 10.1016/j.clinthera.2008.12.004.
- Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care. 2008;31:430–432. doi: 10.2337/dc07-1899.
- Peyrot M, Rubin RR. Factors associated with persistence and resumption of insulin pen use for patients with type 2 diabetes. Diabetes Technol Ther. 2011;13:43–48. doi: 10.1089/dia.2010.0128.
- Oyer D, Narendran P, Qvist M, Niemeyer M, Nadeau DA. Ease of use and preference of a new versus widely available pre-filled insulin pen assessed by people with diabetes, physicians and nurses. Expert Opin Drug Deliv. 2011;8:1259–1269. doi: 10.1517/17425247.2011.615830.
- Bailey T, Thurman J, Niemeyer M, Schmeisl G. Usability and preference evaluation of a prefilled insulin pen with a novel injection mechanism by people with diabetes and healthcare professionals. Curr Med Res Opin. 2011;27:2043–2052. doi: 10.1185/03007995.2011.616190.
- Nadeau DA, Campos C, Niemeyer M, Bailey T. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning. Curr Med Res Opin. 2012;28:3–13. doi: 10.1185/03007995.2011.644427.
- Lajara R, Guerrero G, Thurman J. Healthcare professional and patient perceptions of a new prefilled insulin pen versus vial and syringe. Expert Opin Drug Deliv. 2012;9:1181–1196. doi: 10.1517/17425247.2012.721774.
- Bailey T, Campos C. FlexTouch® for the delivery of insulin: technical attributes and perception among patients and healthcare professionals. Expert Rev Med Devices. 2012;9:209–217. doi: 10.1586/erd.12.13.
Source: PubMed